Navigation Links
InterMune Announces Progress on Pirfenidone in IPF
Date:4/21/2008

- Initiating planned roll-over study for CAPACITY patients in Q3 -

- Patient retention and conduct of Phase 3 CAPACITY program remain

excellent to date - - Abstract of Shionogi Phase 3 pirfenidone study now available on ATS

website -

BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will initiate an open-label roll-over study to evaluate the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). The roll-over study will be open to patients who complete one of the two concurrent Phase 3 CAPACITY studies of pirfenidone in IPF. InterMune expects that the first patient will enter the roll-over study in August 2008. Additional information regarding the design and objectives of the pirfenidone roll-over study will be available at http://www.clinicaltrials.gov within approximately one week. The anticipated 2008 costs of conducting the study are included in InterMune's expense guidance of February 7, 2008.

Regarding the progress of CAPACITY, the company noted that patient retention and overall study conduct remain excellent, with a low rate of patient dropouts to date. InterMune anticipates that top-line results from CAPACITY will be available in January 2009. Data from the CAPACITY trials will remain blinded during the extension study enrollment period.

The company also provided an update on the publication plans of Shionogi concerning its Phase 3 study of pirfenidone in IPF performed in Japan. The abstract of the Tuesday, May 20 presentation by Shionogi of the results of this study at the American Thoraci
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
2. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
3. InterMune Announces Start of Phase 1b Trial of ITMN-191
4. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
5. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
6. Aida Announces New Anti-Cancer Drug Under Development
7. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
8. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
10. ViroPharma Announces Discontinuation of HCV-796 Development
11. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
(Date:1/23/2015)... JUNCTION, N.J. , Jan. 23, 2015  CytoSorbents ... company commercializing its CytoSorb® extracorporeal cytokine adsorber to ... patients, announced the receipt of $385,642, net of ... participant of the Technology Business Tax Certificate Transfer ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... released a new blog post presenting the basic features of ... an accidental death and dismemberment rider for a car insurance ... benefits if the insured dies in an accident. Accidental death ... insurance. , AD&D is not expensive and can be ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... neutrality during wakefulness and is restored during sleep, suggests ... 9, 2010, in San Antonio, Texas, at SLEEP 2010, ... Societies LLC. Results indicate that prior wakefulness caused ... slightly but significantly greenish tint. Overnight sleep restored ...
... satisfaction is related to the amount of sleep they ... research abstract that will be presented Wednesday, June 9, ... 24th annual meeting of the Associated Professional Sleep Societies ... new parents was strongly associated with objective total sleep ...
... rate of disease progression in a clinical trial of ... Hopkins, Roswell Park Cancer Institute and Duke University. ... blood supply to prostate tumors by blocking new blood ... blood vessels to supply nutrients. The multicenter trial ...
... Stress-reducing psychological intervention helps to increase survival and ... cancer over the long-term, according to results of ... Cancer Research , a journal of the American ... intervention arm evidenced significant emotional improvement and more ...
... quality of human life ― especially embryonic stem cells, which ... However, basic scientific problems still remain unresolved but Tel ... "In order to use embryonic stem cells as ... strategies to control their differentiation so we get exactly the ...
... Drug Administration,s abilities to discover potential threats to food ... by impediments to efficient use of its limited resources ... on risks, says a new report by the Institute ... more proactively tackle food safety problems, FDA should implement ...
Cached Medicine News:Health News:Sleep colors your view of the world: Study suggests sleep may restore color perception 2Health News:First-time parents' daily sleep duration predicts their relationship satisfaction 2Health News:Drug that restricts blood supply to prostate tumors delays disease progression 2Health News:Psychological intervention provides enduring health benefits for women with breast cancer 2Health News:A launchpad for stem cell research 2Health News:FDA should adopt risk-based approach to food safety 2Health News:FDA should adopt risk-based approach to food safety 3
... Soft white rubber tube with Murphy eye. ... tube. Two high volume cuffs (One inside other) ... is designed to allow maximum access and optimum ... ventilation. The tube shaft has a special laser-guard ...
Tube for Right Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. X-ray opaque line. Graduated. Single use. S...
Tube for Left Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. X-ray opaque line. Graduated. Single use. St...
... For Rapid Medication Delivery., ,Designed ... cuffed tube incorporates an additional lumen ... delivery below the cuff., ,SHERIDAN ... allow for CO2 monitoring, pressure monitoring ...
Medicine Products: